Perspective Therapeutics, Inc. (CATX)
(Real Time Quote from BATS)
$3.52 USD
-0.30 (-7.85%)
Updated Aug 7, 2025 12:52 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CATX 3.52 -0.30(-7.85%)
Will CATX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
Other News for CATX
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy
Perspective Therapeutics Announces Acceptance of VMT-?-NET Data for Presentation at the ESMO ...
Trust healthcare analyst holds analyst/industry conference call
Perspective Therapeutics management to meet with Piper Sandler
Perspective Therapeutics management to meet with Piper Sandler